Literature DB >> 20102442

The relaxation induced by uroguanylin and the expression of natriuretic peptide receptors in human corpora cavernosa.

Clauber M Sousa1, Alexandre Havt, Cláudia F Santos, F J Arnaud-Batista, Karina M A Cunha, João Batista G Cerqueira, Manassés C Fonteles, Nilberto R F Nascimento.   

Abstract

INTRODUCTION: Receptors for natriuretic peptides have been demonstrated as potential targets for the treatment of male erectile dysfunction. AIM: This study investigates the relaxant effects of the atrial natriuretic peptide (ANP) and uroguanylin (UGN), and expression of natriuretic peptide receptors on strips of human corpora cavernosa (HCC). MAIN OUTCOME MEASURES: Quantitative analysis of natriuretic receptor expression and relaxation of precontracted strips were used to assess the membrane-bound guanylate cyclase-cyclic guanosine monophosphate (cGMP) pathway in HCC strips.
METHODS: HCC was obtained from a cadaver donor at the time of collection of organs for transplantation (14-47 years) and strips were mounted in organ baths for isometric studies.
RESULTS: ANP and UGN both induced concentration-dependent relaxation on HCC strips with a maximal response attained at 300 nM, corresponding to 45.4±4.0% and 49±4.8%, respectively. The relaxation is not affected by 30 µM 1H-[1,2,4]oxaolodiazolo[4,3-a]quinoxalin-1-one (ODQ) (a soluble guanylate cyclase inhibitor), but it is significantly blocked by 10 µM isatin, a nonspecific particulate guanylate cyclase (pGC) inhibitor. UGN was unable to potentiate electrical field stimulation (EFS) or acetylcholine-induced relaxations. The potential role of pGC activation and cGMP generation in this effect is reinforced by the potentiation of this effect by phosphodiesterase-5 inhibitor vardenafil (55.0±7.5-UGN vs. 98.6±1.4%-UGN+vardenafil; P<0.05). The relaxant effect was also partially (37.6%) blocked by the combination iberitoxin-apamin but was insensitive to glybenclamide. The expression of guanylate cyclase receptors (GC-A, GC-B, GC-C) and the expression of the natriuretic peptide "clearance" receptor (NPR-C) were confirmed by real-time polymerase chain reaction. The exposure of HCC strips to ANP (1 µM) and UGN (10 µM) significantly increased cGMP, but not cyclic adenosine monophosphate (cAMP) levels.
CONCLUSIONS: UGN relaxes HCC strips by a guanylate cyclase and K(ca)-channel-dependent mechanism. These findings obtained in HCC reveal that the natriuretic peptide receptors are potential targets for the development of new drugs for the treatment of erectile dysfunction.
© 2010 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102442     DOI: 10.1111/j.1743-6109.2009.01672.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

1.  Agonist-specific compartmentation of cGMP action in myometrium.

Authors:  Iain L O Buxton; Deanna Milton; Scott D Barnett; Stephen D Tichenor
Journal:  J Pharmacol Exp Ther       Date:  2010-07-22       Impact factor: 4.030

Review 2.  The future is today: emerging drugs for the treatment of erectile dysfunction.

Authors:  Maarten Albersen; Alan W Shindel; Kuwong B Mwamukonda; Tom F Lue
Journal:  Expert Opin Emerg Drugs       Date:  2010-09       Impact factor: 4.191

Review 3.  Pendrin, a novel transcriptional target of the uroguanylin system.

Authors:  Julia Rozenfeld; Osnat Tal; Orly Kladnitsky; Lior Adler; Edna Efrati; Stephen L Carrithers; Seth L Alper; Israel Zelikovic
Journal:  Cell Physiol Biochem       Date:  2013-12-18

4.  Defying the stereotype: non-canonical roles of the Peptide hormones guanylin and uroguanylin.

Authors:  Nirmalya Basu; Sandhya Srikant Visweswariah
Journal:  Front Endocrinol (Lausanne)       Date:  2011-06-15       Impact factor: 5.555

Review 5.  From Escherichia coli heat-stable enterotoxin to mammalian endogenous guanylin hormones.

Authors:  A A M Lima; M C Fonteles
Journal:  Braz J Med Biol Res       Date:  2014-03-03       Impact factor: 2.590

Review 6.  Current understanding of guanylin peptides actions.

Authors:  Aleksandra Sindic
Journal:  ISRN Nephrol       Date:  2013-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.